Exozymes Inc. also files under IZTC; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | Heltzen Michael | Chief Executive Officer | Buy(P) | 251 | $7.35 | $2K |
| Aug 26, 2026 | Heltzen Michael | Chief Executive Officer | Buy(P) | 250 | $7.60 | $2K |
| Aug 26, 2026 | Heltzen Michael | Chief Executive Officer | Buy(P) | 4 | $7.58 | $30 |
| Aug 25, 2026 | Heltzen Michael | Chief Executive Officer | Buy(P) | 100 | $7.50 | $750 |
| Aug 25, 2026 | Heltzen Michael | Chief Executive Officer | Buy(P) | 250 | $7.52 | $2K |
| Aug 19, 2026 | Perriman Damien Alan | Chief Commercial Officer | Option exercise(M) | 20K | — | — |
| Aug 19, 2026 | Korman Tyler Paz | Chief Scientific Officer | Option exercise(M) | 33K | — | — |
| Aug 19, 2026 | Perriman Damien Alan | Chief Commercial Officer | Option exercise(M) | 20K | — | $0 |
| Aug 19, 2026 | Korman Tyler Paz | Chief Scientific Officer | Option exercise(M) | 33K | — | $0 |
| Aug 19, 2026 | Heltzen Michael | Chief Executive Officer | Grant(A) | 9K | $6.40 | $57K |
| Apr 9, 2026 | Korman Tyler Paz | Chief Scientific Officer | Sell(S) | 750 | $10.53 | $8K |
| Apr 8, 2026 | Korman Tyler Paz | Chief Scientific Officer | Sell(S) | 750 | $10.04 | $8K |
| Apr 1, 2026 | Nawaz Fouad | Vice President- Finance | Grant(A) | 6K | $8.44 | $51K |
| Apr 1, 2026 | Korman Tyler Paz | Chief Scientific Officer | Grant(A) | 5K | $8.44 | $45K |
| Apr 1, 2026 | Opgenorth Paul Hideo | Vice President, Development | Grant(A) | 4K | $8.44 | $34K |
| Apr 1, 2026 | Perriman Damien Alan | Chief Commercial Officer | Grant(A) | 63K | — | $0 |
| Apr 1, 2026 | Perriman Damien Alan | Chief Commercial Officer | Grant(A) | 146K | — | $0 |
| Apr 1, 2026 | Perriman Damien Alan | Chief Commercial Officer | Grant(A) | 9K | $8.44 | $75K |
| Jul 2, 2025 | Heltzen Michael | Chief Executive Officer | Buy(P) | 1K | $10.22 | $11K |
| Jun 17, 2025 | Heltzen Michael | Chief Executive Officer | Grant(A) | 236K | — | $0 |
| Jun 16, 2025 | Korman Tyler Paz | Vice President, Research | Grant(A) | 3K | $12.54 | $37K |
| Jun 13, 2025 | Nawaz Fouad | Vice President, Finance | Grant(A) | 3K | $12.54 | $44K |
| Jun 13, 2025 | Opgenorth Paul Hideo | Vice President, Development | Grant(A) | 3K | $12.54 | $37K |
| Jan 17, 2025 | Heltzen Michael | Chief Executive Officer | Buy(P) | 2K | $10.78 | $19K |
| Jan 16, 2025 | Heltzen Michael | Chief Executive Officer | Buy(P) | 121 | $10.72 | $1K |
| Nov 15, 2024 | Heltzen Michael | Chief Executive Officer | Buy(P) | 2K | $11.10 | $22K |
| Nov 8, 2024 | MDB Capital Holdings, LLC | 10% Owner | Conversion(C) | 123K | $6.40 | $785K |
| Nov 8, 2024 | Opgenorth Paul Hideo | Vice President, Development | Conversion(C) | 2K | $6.40 | $15K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Exozymes Inc., SEC CIK 0002010788. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under EXOZ and shows every filing by that issuer (also filed as IZTC).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-15. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for EXOZ